FDA Sets Path for Biotech Drug Copies
February 10, 2012
The Food and Drug Administration on Thursday created the first shortcut to the U.S. market for “biosimilar” drugs—cheaper versions of expensive and complex medicines made from biological matter. (Wall Street Journal)
